We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Philips and Dako Collaboration to Improve Pathology Diagnostics

By LabMedica International staff writers
Posted on 29 Jul 2010
Royal Philips Electronics (Eindhoven, the Netherlands) and Dako (Glostrup, Denmark), a private Danish company specializing in tissue-based cancer diagnostics, have signed an agreement to integrate a selection of Dako's image analysis applications into Philips' proposed digital pathology solutions. More...


A fast pathology slide scanner and associated image management system form the basis of Philips' planned integrated solutions for digitizing pathology workflows. The Philips-Dako collaboration will initially focus on leveraging Dako's image analysis software for tissue-based breast cancer diagnosis using its reagents for staining HER2, estrogen receptor (ER), progesterone receptor (PR), p53, and Ki-67 proteins.

Detection and quantification of proteins in biopsy tissue will help classify breast cancers and select appropriate therapy. Philips and Dako are considering an extension of the collaboration to include image analysis software for immunohistology-based prostate and colon cancer diagnostics.

The aim of the partnership is to enhance the operational efficiency and productivity of pathology departments, as well as increase diagnostic confidence. Digitizing the images that pathologists normally view through a microscope should enable the introduction of objective and quantitative image analysis tools.

Royal Philips Electronics is a diversified health and well-being company, focused on improving people's lives through development of new essential products. The company is a market leader in cardiac care, acute care, and home healthcare.

Dako is a global leader in tissue-based cancer diagnostics. Laboratories worldwide use Dako's expertise, reagents, instruments, and software to make precise diagnoses and determine the most effective treatment for patients suffering from cancer.

Related Links:

Royal Philips Electronics
Dako


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Multi-Chamber Washer-Disinfector
WD 390
New
Chromogenic Culture System
InTray™ COLOREX™ ECC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.